Melanotan II nasal spray: convenience vs. real safety trade-offs

What did @stanmilsom1 actually say?

Stan's pitch is straightforward: he uses Melanotan 2 (MT2) as a nasal spray instead of injecting it because he's already pinning other peptides daily and wants to reduce injection frequency. He says the nasal route is "slightly less effective than pinning it" but claims visible results justify the trade-off. He describes a loading phase of two to three sprays daily for a few days, combined with sunbed sessions to build a base tan, then drops to maintenance at roughly three sprays a few times per week with a sunbed every 10 to 14 days.

This is a fairly honest self-assessment, at least compared to most MT2 content online. He is not claiming the nasal spray is equivalent to injection, and he acknowledges the efficacy gap himself. That said, what he is normalizing, a regular sunbed habit combined with a melanocortin agonist, deserves a harder look than he gives it.

Does the science back this up?

On the bioavailability question, Stan is broadly correct: nasal delivery of MT2 is less effective than subcutaneous injection. Research on peptide nasal absorption consistently shows that mucosal barriers, enzymatic degradation in nasal tissue, and molecular weight all limit how much of a peptide actually reaches systemic circulation. Dorr et al. (1996, Journal of Laboratory and Clinical Medicine) established subcutaneous MT2 as the reference standard for melanocortin-1 receptor activation. No published pharmacokinetic study has directly compared nasal versus subcutaneous MT2 bioavailability in humans, so the exact magnitude of the drop-off is genuinely unknown.

MT2 does stimulate melanogenesis through MC1R agonism. That mechanism is well-documented. What is also documented is that MT2 is not approved by any regulatory authority for human use. It carries a meaningful side effect profile including nausea, facial flushing, spontaneous erections, and potential effects on existing nevi (moles). Langan et al. (2015, British Medical Journal) flagged unregulated MT2 use as a public health concern, particularly regarding mole changes and skin cancer risk when combined with UV exposure.

What did they get wrong (or right)?

Stan gets credit for one thing: he does not claim the nasal spray matches injection. That is more honesty than most creators in this space offer. The loading phase concept also has some logic behind it, building receptor saturation before UV exposure is how MT2 is typically discussed in pharmacology literature, though no clinical trial has validated this specific consumer protocol.

What he gets wrong, or more accurately what he leaves out entirely, is the combination risk. Using a melanocortin agonist that accelerates melanogenesis while simultaneously using UV radiation from sunbeds is not a neutral convenience stack. The UK Health Security Agency has repeatedly warned that MT2 plus UV exposure may amplify DNA damage in melanocytes beyond what either exposure would cause alone. He shows results. He does not mention mole monitoring, dermatology check-ins, or the fact that sunbeds are classified as Group 1 carcinogens by the International Agency for Research on Cancer (IARC, 2009).

What should you actually know?

MT2 is not approved for human use in the US, UK, EU, or Australia. Buying it as a nasal spray or in any other form puts you in a regulatory grey zone at best. The peptide works on a real biological mechanism, MC1R activation, but the risk profile is not trivial. Regular sunbed use already carries an established skin cancer risk. Adding a compound that accelerates melanocyte activity on top of that has not been studied in long-term human trials.

If you have moles, a personal or family history of melanoma, or fair skin, the combination Stan describes is particularly inadvisable. Anyone considering MT2 for any reason should have a dermatologist baseline their skin first. The convenience argument Stan makes is understandable, but 108,000 people watched him skip past the part where this compound can change the appearance of moles, which is one of the warning signs clinicians use to catch melanoma early.